CD Biosynsis offers accelerated Sf9 Cells Strain Development and Screening Services, utilizing advanced genome editing and high-throughput platforms to optimize cell lines (Spodoptera frugiperda derived) for superior recombinant protein production. Sf9 cells are the host of choice for the Baculovirus Expression Vector System (BEVS), widely used for producing complex proteins, VLPs (Virus-Like Particles), and vaccine antigens. Our services leverage high-precision genome editing (CRISPR-Cas9, Base Editing) with automated High-Throughput Screening (HTS) technologies to rapidly generate, evaluate, and optimize thousands of genetic variants. We specialize in engineering Sf9 cell lines for enhanced specific productivity ($\text{Q}_\text{p}$), improved product quality (e.g., humanized glycoprofile), prolonged cell viability post-infection, and robustness against industrial stressors, providing a fast track to the commercial Master Cell Bank (MCB).
Get a QuoteStrain development in Sf9 cells aims to maximize the yield and quality of the final product while mitigating the limitations of the Baculovirus Expression Vector System (BEVS), primarily the lytic nature of the infection and non-mammalian PTMs. Our integrated platform significantly accelerates the optimization cycle by utilizing CRISPR-mediated humanized glycoengineering (Knockout/Knock-in of glycosylation genes) and viability enhancement (targeting apoptosis/stress response genes). We couple this with automated liquid handling, miniaturized culture systems, and multi-parameter HTS assays to quickly evaluate monoclonal cell lines for critical quality attributes (CQAs) and specific productivity ($\text{Q}_\text{p}$) post-infection. This rapid, data-driven approach dramatically reduces the timeline for establishing a verified, high-performance Sf9 cell line.
CRISPR-Cas9 Editing (KI/KO)
Used for stable integration of glycosylation pathways into safe harbor loci (KI) and multi-locus deletion of native proteases/glycoenzymes (KO) in insect cells.
Base Editing (BE) / CRISPRi
For high-precision, single-nucleotide substitutions (BE) or tunable repression (CRISPRi) used to fine-tune regulatory elements and chaperone expression levels.
Optimized Delivery (RNP/Plasmid)
Preference for RNP delivery ensures transient activity and high on-target specificity, maximizing safety and editing speed in the insect cell genome.
Automated Single-Cell Cloning
Use of automated cell sorters (e.g., FACS) and limiting dilution to isolate single, viable cells into microplates, ensuring the generation of true monoclonal cell lines.
Productivity Assays (ELISA/Activity)
Implementation of rapid, high-throughput assays to quantify specific productivity ($\text{Q}_\text{p}$) and final titer of the target protein post-infection.
Glycoprofile HTS Analysis
Miniaturized analytical assays for early screening of Critical Quality Attributes (CQAs), focusing on the efficiency of humanized glycosylation and the absence of native insect glycans.
Humanized Glycoengineering
Systematic editing (KO of native, KI of human enzymes) to produce therapeutic proteins and VLPs with human-compatible N-glycans.
Extended Post-Infection Viability
Engineering host cell survival pathways or metabolism to extend the window of high productivity after baculovirus infection, boosting final titer.
Enhanced Folding Capacity
Targeted tuning of ER-resident chaperones (e.g., BiP) and PDI expression to improve the yield and solubility of complex, multi-subunit proteins.
Integrated cycle for rapid, iterative strain optimization using advanced tools.
1. Rational Design & Library Generation
2. Genomic Modification & Selection
3. High-Throughput Screening & Cloning
4. Clonal Verification & MCB Delivery
Computational modeling identifies optimal genetic modifications (KO, KI, tuning) and designs the expression strategy (e.g., chaperone co-expression).
Design gRNAs/primers and construct DNA libraries (e.g., repression levels) for targeted editing.
Select stable genomic integration sites for humanized pathways.
Construct expression vector or RNP/donor complex; deliver editing system into Sf9 cells (Build).
Execute multiplexed gene editing and select for stable integration clones using antibiotic markers or FACS.
Genotype the bulk population to confirm successful editing and integration.
Analyze HTS data to correlate genotype with desired phenotype ($\text{Q}_\text{p}$, glycoprofile) and select the lead clone (Learn).
Genomic verification (sequencing) and stability testing of the final clone over multiple passages.
Delivery of the verified Sf9 master cell bank (MCB) and comprehensive documentation.
Integrated Humanized Glycans
Combines metabolic modeling and multiplex editing (KO/KI) to deliver stably integrated humanized glycosylation pathways, solving the key quality limitation of BEVS.
Folding & Assembly Optimization
Targeted engineering of ER folding machinery maximizes the yield of complex, difficult-to-express proteins and self-assembling structures like VLPs.
Extended Productive Window
Engineering anti-apoptosis/stress pathways ensures enhanced cell survival during the high-stress viral infection phase, leading to higher final titer.
Stable Monoclonal Lines
Focus on CRISPR/HDR integration and automated single-cell cloning ensures genetic stability and true clonality for consistent industrial production.
1. What is the role of HTS in insect cell line development?
HTS rapidly screens thousands of single-cell clones post-editing/transfection. It identifies the rare, optimal clones with the highest specific productivity ($\text{Q}_\text{p}$) and desired quality attributes (e.g., correct glycosylation) in miniaturized culture systems.
2. How do you integrate the humanized glycosylation pathway stably?
We use a sequential or multiplex CRISPR/HDR approach to stably knock-in the required human glycosyltransferase genes into safe harbor loci within the insect cell chromosome, making the trait permanent.
3. Why is it important to extend viability post-infection?
The lytic cycle of the baculovirus naturally leads to cell death shortly after peak expression. Extending viability (by engineering anti-apoptosis/stress pathways) extends the window of high productivity, boosting final product titer.
4. Can you optimize the insect cell host for VLP (Virus-Like Particle) production?
Yes. VLP production is highly dependent on correct subunit folding and assembly. We use Base Editing and CRISPRi to tune the expression of host chaperones and folding enzymes, maximizing the yield and structural integrity of the VLP.
5. How is the final monoclonal cell line verified?
Verification includes sequencing of the edited loci to confirm genotype, stability testing (productivity over passages), and functional assays (e.g., Glycan analysis or VLP assembly confirmation) to confirm phenotype.
6. What is the role of Base Editing in insect cell strain tuning?
Base Editing allows for the subtle, single-nucleotide tuning of regulatory sequences (promoters) or coding sequences (e.g., reducing enzyme activity) to balance metabolic flux and chaperone levels safely.
7. What input is required to start a strain development project?
We require the specific insect cell line (Sf9, Hi5), the gene of interest (GOI) sequence, and the primary optimization goals (e.g., humanized glycosylation, increase VLP yield, improve solubility).
8. What is included in the Master Cell Bank (MCB) delivery?
The MCB consists of a cryopreserved batch of the final verified clonal cell line, accompanied by a comprehensive report detailing all genomic modifications, stability data, and performance metrics.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.